Posts Tagged ‘ biotechnology ’

Cyclin-dependent Cancer Confab Preview

0
April 16, 2010
Cyclin-dependent Cancer Confab Preview

For more than a century, the American Association of Cancer Research has held its annual meeting and this weekend will kick off the 101st event in Washington, DC, which is being held April 17-21, 2010.  Many pharmaceutical and biotechnology companies will be presenting new data and approximately 6,300 abstracts will be discussed in...
Read More »

Cancer Vaccine Therapies: Failures and Future Opportunities

2
April 7, 2010
Cancer Vaccine Therapies: Failures and Future Opportunities

(Note: the following text is an Executive Summary from our new 150-page report titled “Cancer Vaccine Therapies: Failures and Future Opportunities”) Since the early 1990s, cancer immunotherapy has provided hope to patients, physicians, and investors as a new treatment modality with limited side effects and superior efficacy.  Cancer immunotherapy broadly includes passive immunization, active...
Read More »

For Biotechnology in 2010, it’s Déjà vu All over Again

2
March 7, 2010
For Biotechnology in 2010, it’s Déjà vu All over Again

“It’s déjà vu all over again” – Yogi Berra With Opening Day less than a month away, it seems only fitting to reference one of the most quoted personalities of our time to describe our analysis of the biotechnology sector in 2010.  In this article, we review our favorable outlook for the industry, draw...
Read More »

Iron Safety Hits AMAG Pharmaceuticals

0
February 4, 2010
Iron Safety Hits AMAG Pharmaceuticals

Shares of AMAG Pharmaceuticals, Inc. (AMAG) traded as low as $37.70 today, down nearly 17% from the prior close of $45.25 due to purported safety concerns regarding Feraheme® , the company’s marketed product for the treatment of iron deficiency anemia in adult patients with chronic kidney disease . Despite the use of recombinant...
Read More »

Biotech Deal Activity Declines…The Pause that Refreshes?

1
January 14, 2010
Biotech Deal Activity Declines…The Pause that Refreshes?

* MD Becker Partners reporting live from the JP Morgan Healthcare Conference This week, nearly 6,500 registrants gathered in San Francisco, California for the JP Morgan Healthcare Conference to hear 25-minute presentations from 338 life science companies.  For industry executives and investors, the annual event serves as a good barometer for the rest of...
Read More »

2009: Biotech’s Stealth Small Cap Rally

2
January 3, 2010
2009: Biotech’s Stealth Small Cap Rally

On the heels of the Dow Jones Industrial Average (DJIA) logging its worst annual performance since 1931 and the NASDAQ Composite (COMP) having its worst year since inception in 1971, it may have seemed counter intuitive to provide a bullish outlook for the biotechnology industry in 2009.  Nonetheless, at the start of the year...
Read More »

Innovative New Medicines are Key to Economic Growth

2
October 12, 2009
Innovative New Medicines are Key to Economic Growth

The life sciences industry plays a critical role in the United States economy.  Innovative new medicines developed by life sciences companies provide better patient outcomes, improved quality of care, increased life expectancy, and lead to economic gains. Currently, the strengths [e.g. innovation, quality of...
Read More »

Three Recent Biotechnology Activist Wins by Carl Icahn

1
August 30, 2009
Three Recent Biotechnology Activist Wins by Carl Icahn

Although a controversial topic, activist hedge funds and private equity firms typically use a small equity stake in an underperforming company to put public pressure on its management and board of directors with the goal of increasing stakeholder value through cost cutting, changes in corporate strategy or management, capital restructuring, asset divestiture and other...
Read More »

Genzyme’s Manufacturing Disruption Highlights Investment Opportunities in Lysosomal Storage Disorders

1
July 20, 2009
Genzyme’s Manufacturing Disruption Highlights Investment Opportunities in Lysosomal Storage Disorders

Proteins are essential components of the human body.  They perform specific biological functions within a cell and each type of protein has a unique function. For example, enzymes are proteins that help biochemical reactions to occur within the body.  But before they can carry out these important functions, proteins must assemble into precise three-dimensional...
Read More »

Spectrum Pharmaceuticals to Benefit from FDA Action on Zevalin?

1
June 30, 2009
Spectrum Pharmaceuticals to Benefit from FDA Action on Zevalin?

According to the American Cancer Society , non-Hodgkin lymphoma is a cancer that starts in cells of the lymph system, which is part of the body’s immune system.  NHL is the fifth most common cancer in both men and women in the United States...
Read More »